Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers

Bio-Techne Corporation (NASDAQ:TECH) is included among Billionaire Larry Robbins’ 10 Dividend Stock Picks.

Piper Sandler Launches Coverage on Bio-Techne (TECH), Prefers Patience on Sector Growth Drivers

On June 11, Piper Sandler initiated coverage of Bio-Techne Corporation (NASDAQ:TECH) with a Neutral rating and a $65 price target. The firm began coverage of the life science tools sector with what it described as a “feet in the shallow end of the pool” approach. Among the companies under coverage, Piper only recommends buying Twist Bioscience, citing its increasing exposure to next-generation drug discovery and development.

According to the analyst, headwinds tied to biotech and academic spending, along with China-related exposure, are likely to improve in the near term. Even so, Piper wants to see some of the sector’s next major growth drivers take shape before becoming more constructive on additional stocks.

The firm argues that investors “can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-COVID.”

Bio-Techne Corporation (NASDAQ:TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

While we acknowledge the risk and potential of TECH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TECH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best S&P 500 Dividend Stocks to Buy Right Now and 10 Best Value Dividend Stocks to Buy Now According to Warren Buffett

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1